 Effects differentiating agent hexamethylene bisacetamide normal myelodysplastic hematopoietic progenitors Hexamethylene bisacetamide HMBA NSC potent polar-planar agent leukemia solid tumor cell lines vitro achievable concentrations HMBA patients myelodysplastic syndrome Previous phase trials HMBA hematologic toxicity normal bone marrows patients solid tumors concern HMBA severe myelotoxicity patients myelodysplastic syndrome patients hematopoietic reserves effects HMBA myelodysplastic normal hematopoietic progenitors vitro HMBA concentrations optimal differentiation vitro mmol/L HMBA concentrations clinical trials mmol/L growth granulocyte-macrophage colony-forming units erythroid burst-forming units patients myelodysplastic syndrome normal subjects HMBA proliferation myelodysplastic normal progenitors concentration identical inhibition normal myelodysplastic hematopoietic progenitors HMBA similar inhibition clonogenic leukemic growth myeloid leukemia cell lines differentiating agent effective differentiation proliferation abnormal hematopoietic progenitors selective inhibitory effects abnormal normal progenitors mechanisms responsible antiproliferative effects HMBA study similar inhibitory effects HMBA normal abnormal hematopoietic progenitors HMBA limited utility elevations peripheral blood cell counts patients myelodysplastic syndrome